Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Arch Neurol ; 61(12): 1898-904, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15596610

RESUMEN

BACKGROUND: Mutations in the PTEN-induced kinase (PINK1) gene located within the PARK6 locus on chromosome 1p35-p36 have recently been identified in patients with recessive early-onset Parkinson disease. OBJECTIVE: To assess the prevalence of PINK1 mutations within a series of early- and late-onset Parkinson disease patients living in North America. DESIGN: All coding exons of the PINK1 gene were sequenced in a series of 289 Parkinson disease patients and 80 neurologically normal control subjects; the mutation frequencies were evaluated in additional controls (100 white and 50 Filipino subjects). RESULTS: We identified 27 variants, including the first reported compound heterozygous mutation (Glu240Lys and Leu489Pro) and a homozygous Leu347Pro mutation in 2 unrelated young-onset Parkinson disease patients. CONCLUSION: Autosomal recessive mutations in PINK1 are a rare cause of young-onset Parkinson disease.


Asunto(s)
Ligamiento Genético/genética , Enfermedad de Parkinson/genética , Proteínas Quinasas/genética , Adolescente , Adulto , Anciano , Secuencia de Aminoácidos , Estudios de Cohortes , Femenino , Frecuencia de los Genes/genética , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Linaje
2.
Cardiovasc Radiat Med ; 4(1): 34-8, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12892771

RESUMEN

INTRODUCTION: Inflammatory and immunological responses of vascular cells are known to play significant roles in atherosclerotic plaque development. Rapamycin with antiinflammatory, immunosuppressive and antiproliferative properties has been shown to reduce neointima formation when coated on stents. This study is designed to test the potential of oral rapamycin to inhibit atherosclerotic plaque development. METHODS: Eight-week-old apoE knock-out mice were fed with 0.25% cholesterol supplemented diet (control diet), control diet containing 50 microg/kg rapamycin (low-dose rapamycin) or 100 microg/kg rapamycin (high-dose rapamycin) for 4 or 8 weeks. Subsets of mice from each group (n=10) were weighed and euthanized. Whole blood rapamycin levels were determined using HPLC-MS/MS, and histological analyses of atherosclerotic lesions in the aortic root were performed. RESULTS: Mice fed with high-dose rapamycin did not gain weight (18.5+/-1.5 vs. 20.6+/-0.9 g, P=.01). Blood levels of rapamycin 117+/-7 pg/ml were detected in the blood of mice fed with high-dose rapamycin for 8 weeks. The plaque area in mice fed with high dose oral rapamycin is significantly less as compared to control (0.168+/-0.008 vs. 0.326+/-0.013 mm2, P=.001 at 4 weeks; 0.234+/-0.013 vs. 0.447+/-0.011 mm2, P=.001 at 8 weeks). Lumen area was inversely proportional to the plaque area. CONCLUSIONS: The results indicate that oral rapamycin is effective in attenuating the progression of atherosclerotic plaque in the mice.


Asunto(s)
Arteriosclerosis/tratamiento farmacológico , Inmunosupresores/administración & dosificación , Sirolimus/administración & dosificación , Administración Oral , Animales , Aorta/efectos de los fármacos , Aorta/patología , Apolipoproteínas E/genética , Ratones , Ratones Noqueados/genética , Resultado del Tratamiento
3.
Ann Neurol ; 54(2): 271-4, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12891685

RESUMEN

Mutations in DJ-1 have been linked to an autosomal recessive form of early-onset parkinsonism. To identify mutations causing Parkinson's disease (PD), we sequenced exons 1 through 7 of DJ-1 in 107 early-onset (age at diagnosis up to 50 years) PD subjects. One subject had a frameshift mutation in the first coding exon and an exon 7 splice mutation both predicted to result in a loss of functional protein. This subject was diagnosed with probable PD at age 24 years with asymmetric onset and an excellent response to levodopa therapy. Our observations suggest that sequence alterations in DJ-1 are a rare cause of early-onset PD.


Asunto(s)
Antígenos de Neoplasias/genética , Enfermedad de Parkinson/genética , Adulto , Edad de Inicio , Anciano , ADN/genética , Exones/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mutación/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA